{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:45:47Z","timestamp":1791549947685,"version":"4.3.4"},"reference-count":106,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":1655,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1038\/s41379-018-0030-x","type":"journal-article","created":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T16:46:54Z","timestamp":1519145214000},"page":"1012-1025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?"],"prefix":"10.1016","volume":"31","author":[{"given":"Marie Colombe","family":"Agahozo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Hammerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reno","family":"Debets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien H M","family":"van Deurzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-018-0030-x_bib1","first-page":"e797","article-title":"Ductal carcinoma in situ of the breast. How does DCIS develop?","volume":"344","author":"Barnes","year":"2012","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1038\/s41379-018-0030-x_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jncimonographs\/lgq024","article-title":"Ductal carcinoma in situ: risk factors and impact of screening","volume":"2010","author":"Virnig","year":"2010","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1038\/s41379-018-0030-x_bib3","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1056\/NEJMoa1206809","article-title":"Effect of three decades of screening mammography on breast-cancer incidence","volume":"367","author":"Bleyer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-018-0030-x_bib4","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0","article-title":"Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy","volume":"76","author":"Page","year":"1995","journal-title":"Cancer"},{"key":"10.1038\/s41379-018-0030-x_bib5","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/cncr.20979","article-title":"Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the nurses' health study","volume":"103","author":"Collins","year":"2005","journal-title":"Cancer"},{"key":"10.1038\/s41379-018-0030-x_bib6","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/cncr.21069","article-title":"The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up","volume":"103","author":"Sanders","year":"2005","journal-title":"Cancer"},{"key":"10.1038\/s41379-018-0030-x_bib7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/PAI.0b013e3181a1743a","article-title":"Characterization of high-grade ductal carcinoma in situ with and without regressive changes: diagnostic and biologic implications","volume":"17","author":"Chivukula","year":"2009","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/s41379-018-0030-x_bib8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1309\/AJCPW4EADZ9BNXXM","article-title":"Regressive change in high-grade ductal carcinoma in situ of the breast: histopathologic spectrum and biologic importance","volume":"144","author":"Wasserman","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/s41379-018-0030-x_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","article-title":"Clinical significance of tumor-infiltrating lymphocytes in breast cancer","volume":"4","author":"Stanton","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1038\/s41379-018-0030-x_bib10","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3892\/ijo.2015.3075","article-title":"The role of inflammation in progression of breast cancer: friend or foe?","volume":"47","author":"Allen","year":"2015","journal-title":"Int J Oncol"},{"key":"10.1038\/s41379-018-0030-x_bib11","doi-asserted-by":"crossref","first-page":"785317","DOI":"10.1155\/2013\/785317","article-title":"New insights into the role of the immune microenvironment in breast carcinoma","volume":"2013","author":"de la Cruz-Merino","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1038\/s41379-018-0030-x_bib12","doi-asserted-by":"crossref","first-page":"e0152500","DOI":"10.1371\/journal.pone.0152500","article-title":"The prognostic value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis","volume":"11","author":"Mao","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1038\/s41379-018-0030-x_bib13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1038\/s41379-018-0030-x_bib14","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1038\/s41379-018-0030-x_bib15","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1038\/s41379-018-0030-x_bib16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"Vesely","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1038\/s41379-018-0030-x_bib17","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-018-0030-x_bib18","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-018-0030-x_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clim.2003.11.013","article-title":"Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer","volume":"111","author":"Reome","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1038\/s41379-018-0030-x_bib20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S1507-1367(10)60011-9","article-title":"Tumour-infiltrating CD4 and CD8 T lymphocytes in breast cancer","volume":"13","author":"Gisterek","year":"2008","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1038\/s41379-018-0030-x_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12282-016-0698-z","article-title":"Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication","volume":"24","author":"Burugu","year":"2017","journal-title":"Breast Cancer"},{"key":"10.1038\/s41379-018-0030-x_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12916-015-0431-3","article-title":"Relevance of tumor-infiltrating lymphocytes in breast cancer","volume":"13","author":"Dushyanthen","year":"2015","journal-title":"BMC Med"},{"key":"10.1038\/s41379-018-0030-x_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1038\/s41379-018-0030-x_bib24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13059-015-0620-6","article-title":"Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy","volume":"16","author":"Angelova","year":"2011","journal-title":"Genome Biol"},{"key":"10.1038\/s41379-018-0030-x_bib25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"10.1038\/s41379-018-0030-x_bib26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1038\/s41379-018-0030-x_bib27","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.4049\/jimmunol.1201449","article-title":"Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer","volume":"190","author":"Yu","year":"2013","journal-title":"J Immunol"},{"key":"10.1038\/s41379-018-0030-x_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-013-2618-7","article-title":"Myeloid-derived suppressor cells in breast cancer","volume":"140","author":"Markowitz","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/s41379-018-0030-x_bib29","first-page":"321","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nat Rev"},{"key":"10.1038\/s41379-018-0030-x_bib30","first-page":"1093","article-title":"Immune infiltration in human tumors: a prognostic factor that should not be ignored","volume":"29","author":"Galon","year":"2009","journal-title":"Oncogene"},{"key":"10.1038\/s41379-018-0030-x_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw192","article-title":"Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer","volume":"109","author":"Bense","year":"2017","journal-title":"J Natl Cancer Inst."},{"key":"10.1038\/s41379-018-0030-x_bib32","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits breast cancer","volume":"533","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1038\/s41379-018-0030-x_bib33","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-018-0030-x_bib34","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ctrv.2012.04.011","article-title":"The role of the tumour inflammatory cell infiltrate in predicting recurrence and survival in patients with primary operable breast cancer","volume":"38","author":"Mohammed","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1038\/s41379-018-0030-x_bib35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1200\/JCO.1996.14.1.85","article-title":"Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas","volume":"14","author":"Pupa","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-018-0030-x_bib36","first-page":"817","article-title":"Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas","volume":"3","author":"M\u00e9nard","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-018-0030-x_bib37","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/bjc.2012.347","article-title":"The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer","volume":"107","author":"Mohammed","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1038\/s41379-018-0030-x_bib38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/cjp2.25","article-title":"Classical pathology and mutational load of breast cancer - integration of two worlds","volume":"1","author":"Budczies","year":"2015","journal-title":"J Pathol Clin Res"},{"key":"10.1038\/s41379-018-0030-x_bib39","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nature10933","article-title":"The clonal and mutational evolution spectrum of primary triple-negative breast cancers","volume":"486","author":"Shah","year":"2012","journal-title":"Nature"},{"key":"10.1038\/s41379-018-0030-x_bib40","doi-asserted-by":"crossref","first-page":"e1253654","DOI":"10.1080\/2162402X.2016.1253654","article-title":"Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis","volume":"6","author":"Hendrickx","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1038\/s41379-018-0030-x_bib41","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-018-0030-x_bib42","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-018-0030-x_bib43","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1200\/JCO.2014.57.6298","article-title":"Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group N9831 adjuvant trastuzumab trial","volume":"33","author":"Perez","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-018-0030-x_bib44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10549-008-0105-3","article-title":"Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer","volume":"116","author":"Calabr\u00f2","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/s41379-018-0030-x_bib45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-018-0030-x_bib46","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.it.2014.09.006","article-title":"Tertiary lymphoid structures in cancer and beyond","volume":"35","author":"Dieu-Nosjean","year":"2014","journal-title":"Trends Immunol"},{"key":"10.1038\/s41379-018-0030-x_bib47","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1116-1","article-title":"Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients","volume":"15","author":"Figenschau","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1038\/s41379-018-0030-x_bib48","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1172\/JCI67428","article-title":"CD4+follicular helper T cell infiltration predicts breast cancer survival","volume":"123","author":"Gu-Trantien","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1038\/s41379-018-0030-x_bib49","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1158\/0008-5472.CAN-11-0431","article-title":"Human solid tumors contain high endothelial venules: association with T-and B-lymphocyte infiltration and favorable prognosis in breast cancer","volume":"71","author":"Martinet","year":"2011","journal-title":"Cancer Res"},{"key":"10.1038\/s41379-018-0030-x_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2016.00407","article-title":"Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention","volume":"7","author":"Saut\u00e8s-Fridman","year":"2016","journal-title":"Front Immunol"},{"key":"10.1038\/s41379-018-0030-x_bib51","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/jclinpath-2015-203089","article-title":"Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer","volume":"69","author":"Lee","year":"2016","journal-title":"J Clin Pathol"},{"key":"10.1038\/s41379-018-0030-x_bib52","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","article-title":"Tumor-infiltrating CD8+lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-018-0030-x_bib53","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","article-title":"Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients","volume":"25","author":"Ali","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-018-0030-x_bib54","article-title":"CD8+lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer","volume":"48","author":"Liu","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1038\/s41379-018-0030-x_bib55","first-page":"1107","article-title":"Prognostic significance of CD8+T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade","volume":"58","author":"Baker","year":"2011","journal-title":"Histopathology"},{"key":"10.1038\/s41379-018-0030-x_bib56","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10549-011-1647-3","article-title":"CD8+ cytotoxic T cell and FOXP3+regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes","volume":"130","author":"Liu","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/s41379-018-0030-x_bib57","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10549-011-1620-1","article-title":"The prognostic significance of B lymphocytes in invasive carcinoma of the breast","volume":"132","author":"Mahmoud","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/s41379-018-0030-x_bib58","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1158\/0008-5472.CAN-07-5206","article-title":"The humoral immune system has a key prognostic impact in node-negative breast cancer","volume":"13","author":"Schmidt","year":"2008","journal-title":"Cancer Res"},{"key":"10.1038\/s41379-018-0030-x_bib59","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0960-9776(96)90045-4","article-title":"Relevance of multiple biological parameters in breast cancer prognosis","volume":"5","author":"Scholl","year":"1996","journal-title":"Breast"},{"key":"10.1038\/s41379-018-0030-x_bib60","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2234","article-title":"T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers","volume":"11","author":"Rody","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1038\/s41379-018-0030-x_bib61","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1365-2559.2006.02410.x","article-title":"Different patterns of inflammation and prognosis in invasive carcinoma of the breast","volume":"48","author":"Lee","year":"2006","journal-title":"Histopathology"},{"key":"10.1038\/s41379-018-0030-x_bib62","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","article-title":"Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse","volume":"24","author":"Bates","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-018-0030-x_bib63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-010-0987-8","article-title":"An evaluation of the clinical significance of FOXP3+infiltrating cells in human breast cancer","volume":"127","author":"Mahmoud","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/s41379-018-0030-x_bib64","doi-asserted-by":"crossref","first-page":"e50946","DOI":"10.1371\/journal.pone.0050946","article-title":"Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1038\/s41379-018-0030-x_bib65","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/bjc.2012.524","article-title":"Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer","volume":"108","author":"West","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1038\/s41379-018-0030-x_bib66","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"10.1038\/s41379-018-0030-x_bib67","first-page":"1","article-title":"Human breast cancer cells educate macrophages toward the M2 activation status","volume":"4","author":"Sousa","year":"2015","journal-title":"J Bone Oncol"},{"key":"10.1038\/s41379-018-0030-x_bib68","doi-asserted-by":"crossref","first-page":"798","DOI":"10.4161\/onci.20427","article-title":"Carcinoma origin dictates differential skewing of monocyte function","volume":"1","author":"B\u00f6gels","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1038\/s41379-018-0030-x_bib69","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10549-010-1154-y","article-title":"Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome","volume":"128","author":"Campbell","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/s41379-018-0030-x_bib70","doi-asserted-by":"crossref","first-page":"e1002194","DOI":"10.1371\/journal.pmed.1002194","article-title":"Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study","volume":"13","author":"Ali","year":"2016","journal-title":"PLoS Med"},{"key":"10.1038\/s41379-018-0030-x_bib71","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-015-0632-x","article-title":"Prognostic significance of tumor-infiltrating CD8+and FOXP3+lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study","volume":"17","author":"Miyashita","year":"2015","journal-title":"Breast Cancer Res"},{"key":"10.1038\/s41379-018-0030-x_bib72","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","article-title":"Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Denkert","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-018-0030-x_bib73","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-018-0030-x_bib74","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1038\/bjc.2013.634","article-title":"Tumour-infiltrating CD8+lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer","volume":"109","author":"Seo","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1038\/s41379-018-0030-x_bib75","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4048\/jbc.2013.16.1.32","article-title":"Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients","volume":"16","author":"Lee","year":"2013","journal-title":"J Breast Cancer"},{"key":"10.1038\/s41379-018-0030-x_bib76","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10549-012-2245-8","article-title":"Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU\/epirubicin\/cyclophosphamide in breast cancer patients","volume":"136","author":"Oda","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/s41379-018-0030-x_bib77","doi-asserted-by":"crossref","unstructured":"Hussein MR, Hassan HI. Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J Clin Pathol. 2006;59:972\u20137.","DOI":"10.1136\/jcp.2005.031252"},{"key":"10.1038\/s41379-018-0030-x_bib78","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10549-013-2556-4","article-title":"FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast","volume":"139","author":"Lal","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/s41379-018-0030-x_bib79","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/(SICI)1096-9896(199702)181:2<200::AID-PATH726>3.0.CO;2-K","article-title":"Angiogenesis and inflammation in ductal carcinomain situ of the breast","volume":"181","author":"Lee","year":"1997","journal-title":"J Pathol"},{"key":"10.1038\/s41379-018-0030-x_bib80","first-page":"321","article-title":"The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast","volume":"7","author":"Pruneri","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-018-0030-x_bib81","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-016-4036-0","article-title":"Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast","volume":"161","author":"Campbell","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/s41379-018-0030-x_bib82","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/modpathol.2015.158","article-title":"The immune microenvironment of breast ductal carcinoma in situ","volume":"29","author":"Thompson","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-018-0030-x_bib83","first-page":"1098","article-title":"Immune escape in breast cancer during in situ to invasive carcinoma transition","volume":"7","author":"Gil Del Alcazar","year":"2017","journal-title":"Am Assoc Cancer Res"},{"key":"10.1038\/s41379-018-0030-x_bib84","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.mpdhp.2012.01.001","article-title":"Ductal carcinoma in situ: current morphological and molecular subtypes","volume":"18","author":"Brown","year":"2012","journal-title":"Diagn Histopathol"},{"key":"10.1038\/s41379-018-0030-x_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cam4.715","article-title":"CD8+tumor-infiltrating lymphocytes contribute to spontaneous \u201chealing\u201d in HER2-positive ductal carcinoma in situ","volume":"5","author":"Morita","year":"2016","journal-title":"Cancer Med"},{"key":"10.1038\/s41379-018-0030-x_bib86","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/his.13217","article-title":"Prognostic significance of Tumour infiltrating B-Lymphocytes in Breast Ductal Carcinoma in Situ","volume":"71","author":"Miligy","year":"2017","journal-title":"Histopathology"},{"key":"10.1038\/s41379-018-0030-x_bib87","first-page":"5210","article-title":"Relationship of the breast ductal carcinoma in situ immune microenvironment with clinico-pathological and genetic features","volume":"23","author":"Hendry","year":"2017","journal-title":"Am Assoc Cancer Res"},{"key":"10.1038\/s41379-018-0030-x_bib88","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/ajcp\/aqw097","article-title":"An examination of the local cellular immune response to examples of both ductal carcinoma in situ (DCIS) of the breast and DCIS with microinvasion, with emphasis on tertiary lymphoid structures and tumor infiltrating lymphoctytes","volume":"146","author":"Kim","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/s41379-018-0030-x_bib89","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.breast.2016.07.015","article-title":"The genomic landscape of breast cancer and its interaction with host immunity","volume":"29","author":"Luen","year":"2016","journal-title":"Breast"},{"key":"10.1038\/s41379-018-0030-x_bib90","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0959-8049(92)90134-N","article-title":"Lymphocyte infiltrates as a prognostic variable in female breast cancer","volume":"28","author":"Aaltomaa","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1038\/s41379-018-0030-x_bib91","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-009-0654-0","article-title":"Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ","volume":"123","author":"Sharma","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/s41379-018-0030-x_bib92","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/2159-8290.CD-17-0222","article-title":"Immune escape in breast cancer during in situ to invasive carcinoma transition","volume":"7","author":"Gil Del Alcazar","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1038\/s41379-018-0030-x_bib93","doi-asserted-by":"crossref","first-page":"e1218106","DOI":"10.1080\/2162402X.2016.1218106","article-title":"The ratio of CD8 C \/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ","volume":"5","author":"Semeraro","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1038\/s41379-018-0030-x_bib94","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/modpathol.2015.79","article-title":"Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score","volume":"28","author":"Knopfelmacher","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-018-0030-x_bib95","first-page":"1","article-title":"Identification of a basal-like subtype of breast ductal carcinoma in situ","volume":"512","author":"Zhou","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1038\/s41379-018-0030-x_bib96","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.bjc.6606021","article-title":"Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease","volume":"104","author":"Clark","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1038\/s41379-018-0030-x_bib97","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3121\/cmr.2008.825","article-title":"Breast cancer subtypes based on ER\/PR and Her2 expression: comparison of clinicopathologic features and survival","volume":"7","author":"Onitilo","year":"2009","journal-title":"Clin Med Res"},{"key":"10.1038\/s41379-018-0030-x_bib98","doi-asserted-by":"crossref","first-page":"469251","DOI":"10.1155\/2014\/469251","article-title":"Breast cancer survival defined by the ER\/PR\/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers","volume":"2014","author":"Parise","year":"2014","journal-title":"J Cancer Epidemiol"},{"key":"10.1038\/s41379-018-0030-x_bib99","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10549-016-3862-4","article-title":"Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study","volume":"158","author":"Doebar","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/s41379-018-0030-x_bib100","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1245\/s10434-013-3119-y","article-title":"Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS","volume":"20","author":"Fracol","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1038\/s41379-018-0030-x_bib101","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1002\/cncr.26734","article-title":"HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ","volume":"118","author":"Sharma","year":"2012","journal-title":"Cancer"},{"key":"10.1038\/s41379-018-0030-x_bib102","doi-asserted-by":"crossref","unstructured":"Lowenfeld L, Mick R, Datta J, et al. Dendritic cell vaccination enhances immune responses and induces regression of HER2 pos DCIS independent of route: results of randomized selection design trial. Clin Cancer Res. 2016:1924.","DOI":"10.1158\/1078-0432.CCR-16-1924"},{"key":"10.1038\/s41379-018-0030-x_bib103","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.1158\/0008-5472.CAN-07-0878","article-title":"Development of vaccines for high-risk ductal carcinoma in situ of the breast rationale for vaccines in patients with ductal carcinoma in situ","volume":"67","author":"Czerniecki","year":"2007","journal-title":"Cancer Res"},{"key":"10.1038\/s41379-018-0030-x_bib104","first-page":"S1044","article-title":"Breast cancer genomics and immuno-oncological markers to guide immune therapies","volume":"6","author":"Hammerl","year":"2017","journal-title":"Semin Cancer Biol"},{"key":"10.1038\/s41379-018-0030-x_bib105","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1078-0432.CCR-07-1465","article-title":"Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast","volume":"14","author":"Vincent-Salomon","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-018-0030-x_bib106","first-page":"3980","article-title":"A molecular portrait of high-grade ductal carcinoma in situ","volume":"18","author":"Abba","year":"2016","journal-title":"Cancer Res Tumor Stem Cell Biol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0030-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0030-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222016878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222016878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0030-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:51:52Z","timestamp":1760230312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222016878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":106,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0893395222016878"],"URL":"https:\/\/doi.org\/10.1038\/s41379-018-0030-x","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-018-0030-x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}